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A B S T R A C T
Background
Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative neoplasms that increase the
risk of arterial and venous thrombosis, as well as bleeding. In addition to the different therapeutic strategies available, an antiplatelet
drug is often used to reduce thrombotic risk.
Objectives
Toquantify the benefit andharmof antiplatelet drugs for long-termprimary and secondary prophylaxis of arterial and venous thrombotic
events in patients with polycythaemia vera or essential thrombocythaemia.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library (Issue 1 2012), MEDLINE (1966
to 2012), and EMBASE (1980 to 2012), as well as online registers of ongoing trials and conference proceedings. The date of the last
search was October 2012.
Selection criteria
We included all randomised controlled trials (RCTs) comparing long-term (>6 months) use of an antiplatelet drug versus placebo or
no treatment in participants with polycythaemia vera or essential thrombocythaemia, as diagnosed by established international criteria,
with data for at least one of the selected outcomes.
Data collection and analysis
Using a pre-defined extraction form, two review authors independently screened results, extracted data, and assessed quality.We planned
to analyse the following outcomes: mortality from arterial and venous thrombotic events (primary efficacy outcome), mortality from
bleeding episodes (primary safety outcome), fatal and non-fatal arterial thrombotic events, fatal and non-fatal venous thrombotic events,
micro-circulation events, transient neurological and ocular manifestations, major and minor bleeding episodes, and all-cause mortality
and any adverse events. We based quantitative analysis of outcome data on an intention-to-treat principle. We used the pooled odds
ratio (OR) with 95% confidence interval (CI) with a fixed-effect model (Mantel-Haenszel) to estimate the overall treatment effect.
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Main results
We identified no new studies from the updated searches. We included in this review two RCTs for a total of 630 participants. Both
RCTs included participants with an established diagnosis of polycythaemia vera and with no clear indication or contraindication to
aspirin therapy. We judged both studies to be of moderate quality. Published data from both studies were insufficient for a time-to-
event data analysis and for some of the primary and secondary outcomes that we planned. The use of low-dose aspirin, compared
with placebo, was associated with a lower risk of fatal thrombotic events (although this benefit was not statistically significant (OR
0.20, 95% CI 0.03 to 1.14; P = 0.07). No data on mortality from bleeding episodes were available. A non-significant benefit of aspirin
was shown for all-cause mortality (OR 0.46, 95% CI 0.21 to 1.01; P = 0.05). No increase in the risk of major bleeding was reported
in participants taking aspirin compared with those given placebo (OR 0.99, 95% CI 0.23 to 4.36; P = 0.99), and a non-significant
increase with aspirin treatment was shown for minor bleeding (OR 1.85, 95% CI 0.90 to 3.79; P = 0.09). No published studies have
reported findings in participants with essential thrombocythaemia or in the study of other antiplatelet drugs.
Authors’ conclusions
For patients with polycythaemia vera who have no clear indication or contraindication to aspirin therapy, available evidence suggests
that the use of low-dose aspirin, when compared with no treatment, is associated with a statistically non-significant reduction in the
risk of fatal thrombotic events and all-cause mortality, without an increased risk of major bleeding.
P L A I N L A N G U A G E S U M M A R Y
Antiplatelet drugs for preventing arterial and venous thrombotic events in patients with polycythaemia vera or essential throm-
bocythaemia
Low-dose aspirin as an antiplatelet therapy is the drug of choice for preventing cardiovascular events, but the potential risk of bleeding
has limited its use in myeloproliferative neoplasms in the past. Evidence from this review of 630 people in two trials suggests that, in
patients with polycythaemia vera and with no clear indication or contraindication to aspirin therapy, low-dose aspirin may reduce the
risk of thrombotic and all-cause mortality. No data were provided on mortality from bleeding episodes. No studies in participants with
essential thrombocythaemia and with antiplatelet therapy other than aspirin have been published.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antiplatelet drugs compared with placebo for polycythaemia vera
Patient or population: patients with polycythaemia vera
Settings: outpatient
Intervention: aspirin
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)°
Comments
Assumed risk Corresponding risk
Placebo Aspirin
Mortality for thrombotic
events
[mean follow-up 31
months]
Medium-risk population OR 0.20 [0.03, 1.14] 630 (2) ⊕⊕⊕©
moderate
22 per 1000 3 per 1000
(-18 to 22)
Mortality for bleedings
[mean follow-up 31
months]
Medium-risk population NA 630 (2) ⊕⊕⊕©
moderate
NA NA
All-cause mortality
[mean follow-up 31
months]
Medium-risk population OR 0.46 [0.21, 1.01] 630 (2) ⊕⊕⊕©
moderate
63 per 1000 30 per 1000
(14 to 64)
Major bleeding
[mean follow-up 31
months]
Medium-risk population OR 0.99 [0.23, 4.36] 630 (2) ⊕⊕⊕©
moderate
9 per 1000 9 per 1000
(2 to 40)
Minor bleeding
[mean follow-up 31
months]
Medium-risk population OR 1.85 [0.90, 3.79] 630 (2) ⊕⊕⊕©
moderate
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38 per 1000 68 per 1000
(34 to 130)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
°The quality of the trials was judged as moderate because only two small trials are available and the risk of bias in both trials is uncertain.
CI: Confidence interval; OR: odds ratio; NA: not available.
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Polycythaemia vera and essential thrombocythaemia are chronic
Philadelphia-negative myeloproliferative neoplasms, in which a
multi-potent haemopoietic stem cell autonomously replicates, in-
dependent of physiological stimuli (WHO 2002). Both diseases
follow a chronic clinical course with increased risk of arterial and
venous thrombosis and a 1% to 2% incidence per year of evolu-
tion to myelofibrosis with myeloid metaplasia or transformation
to acute leukaemia (GISP 1995; Passamonti 2004; Finazzi 2005;
Marchioli 2005). Also, the risk of bleeding is increased as the result
of quantitative and qualitative platelet abnormalities.
The leading symptoms of polycythaemia vera are secondary to
increased red cell production and red cell mass. The consequent
blood hyperviscosity reduces blood flow velocity and increases the
risk of both microvascular and thrombotic complications. The
incidence of polycythaemia vera is 2.3 per 100,000 person-years
(Ania 1994). The overall mortality in study participants treated
with various regimens was estimated to be 3.5 deaths per 100
persons per year - almost twice the risk of the general population
(ECLAP, European Collaboration on Low-dose Aspirin in Poly-
cythaemia study) (Marchioli 2005). Thrombotic events, haema-
tological transformation, and major bleeding are responsible for
41%, 13%, and 4% of deaths, respectively (Marchioli 2005). Par-
ticipants are usually stratified into different thrombotic risk cate-
gories on the basis of the combination of age, a history of arterial
or venous thrombosis, and the presence of other common cardio-
vascular risk factors (e.g. smoking, diabetes mellitus, congestive
heart failure) (Campbell 2005; Marchioli 2005).
The incidence of essential thrombocythaemia is 2.5 per 100,000
person-years (Mesa 1999). The hallmark of essential thrombo-
cythaemia is an elevated peripheral platelet count together with
excessive proliferation of the megakaryocytes. The occurrence of
thrombotic complications is related to platelet count and func-
tion but is not dependent on the degree of platelet elevation. In
about two thirds of all participants, the clinical course is charac-
terised by the occurrence of minor andmajor thrombotic or bleed-
ing complications, but in about one third, the disease is benign,
and no complications are reported for many years (Mesa 1999;
Passamonti 2004). Similar to polycythaemia vera, thrombotic risk
categories can be identified on the basis of age, a history of arterial
or venous thrombosis, and the presence of common cardiovascular
risk factors (e.g. smoking, hypertension, hypercholesterolaemia)
(Cortelazzo 1990; Cortelazzo 1995; Campbell 2005).
Description of the intervention
In keeping with the estimated individual risk of thrombotic and
bleeding complications, different therapeutic strategies are used:
phlebotomy for polycythaemia vera or platelet apheresis for essen-
tial thrombocythaemia, cytoreductive therapy (e.g. hydroxyurea,
anagrelide, interferon-α), and antiplatelet drugs to prevent platelet
aggregation (Campbell 2005).
Several molecules that inhibit platelet aggregation are currently
available in clinical practice, including aspirin, dipyridamole,
and the old (ticlopidine, clopidogrel) and the new (prasugrel,
ticagrelor) thienopyridines (ACCP 2012). Aspirin has an an-
tiplatelet effect by inhibiting the production of thromboxane,
thienopyridine by inhibiting adenosine diphosphate (ADP) recep-
tor/P2Y12 inhibitors, and dipyridamole by inhibiting the produc-
tion of thromboxane and by inhibiting the phosphodiesterase en-
zymes that normally break down cyclic adenosine monophosphate
(cAMP). In addition to the increased risk of bleeding, major re-
ported adverse events include the following: for aspirin, gastric ul-
cer and allergic reaction; for thienopyridine, neutropenia, throm-
botic thrombocytopenic purpura, and dyspnoea (ticagrelor); and
for dipyridamole, headache and dizziness (ACCP 2012).
How the intervention might work
Antiplatelet drugs are commonly used for primary and secondary
prevention of arterial thrombosis in patients without myeloprolif-
erative neoplasms. For example, among a wide range of high-risk
patients (with acute or previous vascular disease or some other pre-
disposing condition), aspirin prevents 10 to 20 fatal and non-fatal
thrombotic events per 1000 patients per year (ATC 2002). There
is no reason to suppose a lack of effect of antiplatelet drugs in
patients with polycythaemia vera or essential thrombocythaemia.
Aspirin has been preferentially used by clinicians and researchers
in participants with polycythaemia vera and essential thrombo-
cythaemia because, in these diseases, biosynthesis of thrombox-
ane is increased, and one of the molecular effects of aspirin on
platelet aggregation is the reduction of thromboxane biosynthesis
(Landolfi 1992; Rocca 1995). However, other antiplatelet drugs
are currently used in daily practice, in particular when aspirin is
contraindicated (Alvarez-Larran 2010).
Why it is important to do this review
It is important to assess the actual beneficial effects of antiplatelet
drugs. As has been stated, different underlying pathophysiologi-
cal mechanisms of arterial and venous thrombosis among patients
with and without myeloproliferative neoplasms may result in dif-
ferent effects of antiplatelet drugs on thrombosis occurrence and
survival.Moreover, inmyeloproliferative neoplasms, bleedingmay
occur spontaneously or may be associated with antiplatelet drugs.
Bleeding is typically mucocutaneous, with easy bruising and nose
and gingival bleeding. Major haemorrhage requiring transfusion
is less frequent and generally involves the gastrointestinal tract.
Age, disease duration, use of an antiplatelet agent, and a history of
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bleeding were significantly associated with bleeding events during
follow-up (Marchioli 2005). Aspirin is associated with an approxi-
mately two-fold increase in the risk of major upper gastrointestinal
bleeding (one to two bleeding events per 1000 patients per year),
with an absolute excess of haemorrhagic strokes of one to two per
10,000 patients with chronic Philadelphia-negativemyeloprolifer-
ative neoplasms (ECLAP 2004; Harrison 2005). Finally, a platelet
count greater than 1,500,000/mm3 is a well-recognised bleeding
risk factor (Campbell 2005).
Therefore, the aim of this systematic review - an update of a pre-
viously published Cochrane review (Squizzato 2008) - is to assess
the efficacy and safety of antiplatelet drugs in the primary and
secondary prevention of thrombotic events in different risk sub-
groups of participants with polycythaemia vera or essential throm-
bocythaemia.
O B J E C T I V E S
To assess the effects of an antiplatelet drug in the long-term pri-
mary and secondary prophylaxis of arterial and venous thrombotic
events in patients with polycythaemia vera or essential thrombo-
cythaemia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
Adult (age ≥18 years) participants with polycythaemia vera or es-
sential thrombocythaemia, diagnosed by established international
criteria (e.g. World Health Organization (WHO), Polycythaemia
Vera Study Group (PVSG)).
Types of interventions
Antiplatelet drug (e.g. aspirin, ticlopidine, clopidogrel, dipyri-
damole, prasugrel, ticagrelor) versus placebo or no treatment for
at least 6 months.
Types of outcome measures
Separate analyses for polycythaemia vera and for essential throm-
bocythaemia were planned. Primary and secondary end-points
were determined for both diseases.
Primary outcomes
• Mortality from arterial and venous thrombotic events (fatal
myocardial infarction (MI), fatal stroke, fatal acute visceral
thromboembolism, fatal acute peripheral thromboembolism,
fatal cerebral sinus and venous thrombosis, fatal visceral vein
thrombosis, fatal pulmonary embolism, fatal venous thrombosis
in unusual sites)
• Mortality from bleeding episodes
Secondary outcomes
Each single fatal and non-fatal arterial and venous thrombotic
event
Arterial
• Myocardial infarction (MI) (fatal and non-fatal).
• Unstable angina.
• Ischaemic stroke (fatal and non-fatal).
• Transient ischaemic attack (TIA).
• Acute peripheral and visceral thromboembolism (fatal and
non-fatal).
Venous
• Deep venous thrombosis (legs and arms).
• Pulmonary embolism (fatal and non-fatal).
• Fatal cerebral sinus and venous thrombosis.
• Unusual sites of venous thrombosis (visceral vein
thrombosis and cerebral sinus and venous thrombosis, fatal and
non-fatal).
• Superficial venous thrombosis.
Each single micro-circulation event
• Erythromelalgia.
• Other.
Each single transient neurological and ocular manifestation
• Seizure.
• Migraine.
• Vertigo.
• Tinnitus.
• Scintillating scotoma.
• Amaurosis fugax.
• Other.
Major and minor bleeding episodes
• Major bleeding (e.g. haemorrhagic stroke, gastric bleeding,
any bleeding requiring blood transfusion, any bleeding causing a
haemoglobin level drop of >2 mg/dL, or hospitalisation).
• Minor bleeding.
All-cause mortality
All adverse events
(e.g. renal failure, thrombotic thrombocytopaenic purpura (TTP),
neutropenia, low platelets, gastric complaints, diarrhoea, skin
rash).
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We considered any RCTs with at least one of the above clinical
outcomes for this review. We excluded RCTs with only laboratory
outcomes.
We contacted Investigators to obtain unpublished data when nec-
essary.
Search methods for identification of studies
Wedeveloped the search strategy for this review in accordance with
theCochraneHaematologicalMalignanciesGroup guidelines.We
searched for RCTs using the following methods.
Electronic searches
We searched The Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library (Issue 1, 2012; see Appendix
1), MEDLINE (1946 to 2012; see Appendix 2), and EMBASE
(1996 to 2012; see Appendix 3). The date of the last search was
12 October 2012.
No language restrictions were applied.
Searching other resources
We searched the Database of Abstracts of Reviews of Effects
(DARE) in The Cochrane Library in October 2012.
We also searched websites for recent or ongoing trials (e.g. http:/
/www.clinicaltrials.gov, http://www.controlled-trials.com) in Oc-
tober 2012.
We searched the online conference proceedings of
• American Society of Hematology (from 2004 to 2011) and
• European Hematology Association (from 2002 to 2011)
as well as references from relevant review articles.
Data collection and analysis
Selection of studies
We selected studies on the basis of Chapter 7 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
Two review authors (AS, ER) independently selected potentially
eligible studies from the search. We rejected studies if one could
determine from the title and/or abstract that the study was not
suitable for inclusion in this review. We obtained the full text of
the study when an article could not be excluded with certainty.
We then compared excluded studies, and any disagreement was
resolved through discussion between the authors. When necessary,
we contacted the trial authors for additional information. To assess
agreement between authors on study selection, we used the k statis-
tic, which measures chance-corrected agreement. A k value higher
than 0.6 was considered to represent substantial agreement, and
values higher than 0.8 almost perfect agreement (Maclure 1987).
We extracted the study characteristics using a pre-defined formand
included an assessment of quality.We used a consensus meeting to
resolve any disagreement in the quality assessment of the trials. The
third author (SM) checked assessments for the included studies.
Data extraction and management
Two authors independently extracted data (AS, ER) using a pre-
defined data extraction form. A consensus meeting was held to
deal with differences in the extracted data.
We extracted data for any subgroup listed in the ’Subgroup analysis
and investigation of heterogeneity’ paragraph.
Extracted data consisted of the following:
• General information: published/unpublished, title, authors,
country, year of publication, duplicate publications.
• Trial characteristics: design, duration, allocation
concealment (and method), randomisation (and method),
blinding (outcome assessors), checking of blinding, intention-to-
treat analysis.
• Intervention: loading dose, dosage, duration of treatment.
• Participants: exclusion criteria, total number and numbers
in comparison groups, age, gender, similarity of groups at
baseline, withdrawals/losses to follow-up, history of thrombotic
events, JAK2 V617F mutation status, concomitant
cardiovascular risk factors, levels of hematocrit (for
polycythaemia vera) and of platelets (for essential
thrombocythaemia), concomitant therapies.
• Outcomes: listed above.
Assessment of risk of bias in included studies
We assessed the methodological quality of selected studies on the
basis of Chapter 8 of theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011b). We scored each of the following
points as ’low,’ ’high,’ or ’unclear’ (where ’low’ indicates that the
study is less open to bias) and report them in a risk of bias table
(Characteristics of included studies; Figure 1):
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
• Method of randomisation (selection bias): Methods of
randomisation using date of birth, date of admission, hospital
numbers, or alternation are not appropriate because they do not
allow each study participant to have the same chance of receiving
each intervention.
• Concealment of allocation (indication bias): Adequate
measures to conceal allocations include central randomisation;
serially numbered, opaque, sealed envelopes; and other
descriptions with convincing concealment.
• Blinding of investigators and participants (performance
bias).
• Blinding of outcome assessment (detection bias).
• Adequate follow-up (attrition bias): Attrition bias refers to
systematic differences between the comparison groups in terms
of loss of participants from the study. We will carefully check the
reporting of withdrawals, dropouts, protocol deviations, and
losses to follow-up. It is adequate when more than 90% of
participants have completed follow-up, and when reasons for
withdrawals, dropouts, protocol deviations, and losses to follow-
up are clearly reported.
• Other possible bias.
To avoid selection bias, we did not reject any study because of
methodological characteristics or any subjective quality criteria,
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except non-randomised studies. However, we planned to examine
differences in study methods in sensitivity analyses.
Measures of treatment effect
We analysed data of selected studies on the basis of Chapter 9
of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
We used the Cochrane Review Manager software to analyse the
data (RevMan 5). We based quantitative analysis of outcome on
the intention-to-treat (ITT) principle. To measure the treatment
effect for each study, we used the OR with 95% CI.
Unit of analysis issues
We planned to manage data with non-standard designs according
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a).
Dealing with missing data
We contacted the investigators for additional information about
missing data, but no data were provided. As only two RCTs were
finally meta-analysed, we decided to analyse only available out-
comes for both studies, as imputing the missing data with replace-
ment values would have provided misleading information.
Assessment of heterogeneity
As trials may have been carried out according to different proto-
cols, we planned to assess statistical heterogeneity of trial data by
using the Mantel-Haenszel Chi2 test of heterogeneity and the I²
statistic of heterogeneity (Deeks 2011). For the first method, trial
data were considered to be heterogeneous if P < 0.10. As signifi-
cant heterogeneity may have occurred, we planned to attempt to
explain the differences as they relate to types of participants and
study design. The I² method is expressed as a percentage of to-
tal variation across studies with an uncertainty interval (Higgins
2003). I² < 30% indicates mild heterogeneity, 30% to 50% mod-
erate heterogeneity, and > 50% severe heterogeneity.
Assessment of reporting biases
We planned to assess publication bias by using funnel plots, if
a sufficient number of RCTs were included (at least 10 studies)
(Lau 2006, Egger 1997, Sterne 2011). We also planned to apply
a rank correlation test if necessary (Lau 2006). However, we did
not assess reporting bias because only two trials were included.
Data synthesis
We planned to extract the hazard ratio (HR) and associated vari-
ances for time-to-event data (i.e. mortality) directly from the trial
publications or, if not reported, to extract them indirectly using
the methods described by Parmar involving either other available
summary statistics or data extracted from published Kaplan-Meier
curves (also with the help of Lesley Stewart’sMicrosoft Excel sheet,
which is available at the Editorial Base of the Cochrane Haema-
tological Malignancies Group) (Parmar 1998).
We planned to obtain a pooledHR from the derived observed (O)
less expected (E) number of events and the variance for each trial,
using the fixed-effect model.
We planned to report ratios of treatment effects for time-to-event
outcomes so that HRs less than 1.0 favour antiplatelet drugs and
values greater than 1.0 favour placebo or no treatment.
For binary endpoints, measure of effect was the OR with 95% CI.
We estimated the overall treatment effect by the pooled OR with
95% CI using a fixed-effect model (Mantel-Haenszel). Each test
for significance was two-sided.
Given that published data from both studies were insufficient for
a time-to-event data analysis or for any of the primary and sec-
ondary outcomes that we planned, and the corresponding authors
of studies did not provide them, we meta-analysed outcomes as
simple binary endpoints.
The main value of this review is derived from the examination
of whether long-term administration of an antiplatelet drug has
consistent effects in primary and secondary thrombotic prevention
and in pre-defined thrombotic risk subgroups.
For this reason, we planned subgroup analyses. However, we per-
formed no subgroup analysis because available data were insuffi-
cient.
Subgroup analysis and investigation of heterogeneity
For each myeloproliferative disease -polycythaemia vera and es-
sential thrombocythaemia - we planned the following subgroup
analyses:
• Antiplatelet drug dosage (low dose vs high dose).
• Antiplatelet drug for primary prophylaxis (to prevent first
thrombotic events).
• Antiplatelet drug for secondary prophylaxis (after an arterial
or a venous thrombotic event).
• JAK2 V617F mutation status.
• Different ages.
• Concomitant cardiovascular risk factors (e.g. hypertension,
dyslipidaemia, diabetes mellitus, smoking).
• Levels of hematocrit (for polycythaemia vera) and of
platelets (for essential thrombocythaemia).
• Concomitant therapies.
Sensitivity analysis
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We re-analysed data using a random-effects model instead of a
fixed-effect model.
Moreover, to test the robustness of the review results, we planned
to re-analyse data by including/excluding studies on the basis of
differences in quality, sample size and studymethods, and imputed
values for missing data. However, as reported in the Dealing with
missing data section, only two RCTs were finally meta-analysed,
limiting any sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
In the previous search of March 2007, we found 536 references
with 74duplicates; on the basis of title and/or abstract, we excluded
441 publications. In the updated search inOctober 2012, we iden-
tified 348 references with 24 duplicates (Figure 2); on the basis of
title and/or abstract, we excluded 324 publications. Overall, we
found 786 references with 98 duplicates; on the basis of title and/
or abstract, we excluded 765 publications. We retrieved full copies
of 21 articles. We excluded nine because they were review articles
without original data, seven because they were not randomised
trials, and one because it was a protocol. From four potentially
eligible RCTs, two studies were further excluded because they did
not meet inclusion criteria (Characteristics of excluded studies).
Only two RCTs were finally included in this systematic review
(GISP 1997; ECLAP 2004). Both studies included only partici-
pants with polycythaemia vera, and in both trials, the administered
antiplatelet drug was aspirin given at low dose (Characteristics of
included studies). We did not find and therefore did not include
any new studies in our update search. An ongoing study, which
was potentially eligible, was identified from a search of the online
trial registry (Characteristics of ongoing studies).
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Figure 2. Study flow diagram (PRISMA).
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Included studies
In the pilot study of the Gruppo Italiano Studio Policitemia
(GISP), 112 participants with a PVSG diagnosis of polycythaemia
vera were randomly assigned to low-dose aspirin (40 mg per day)
or to placebo (GISP 1997). In keeping with the ’uncertainty prin-
ciple,’ people were eligible if physicians were uncertain whether
aspirin was indicated, and were ineligible if physicians were rea-
sonably certain that aspirin was indicated, was not indicated, or
was contraindicated. Exclusion criteria included stage III chronic
renal failure, active gastrointestinal disease, and a history of a ma-
jor haemorrhagic episode during the preceding four months. The
primary objective of the study was to evaluate safety and tolerabil-
ity by assessing major haemorrhagic events, compliance with the
assigned treatment, and gastric intolerance. Secondary endpoints
consisted of the occurrence of acute MI, TIAs, stroke, venous
thromboembolism, and acute arterial thrombosis. Aspirin admin-
istration was not associated with any bleeding complications. The
mean duration of follow-up was 16 months.
In the ECLAP phase III study, 518 participants with a PVSG di-
agnosis of polycythaemia vera were randomly assigned to low-dose
aspirin (100 mg per day) or to placebo (ECLAP 2004). Partici-
pants were eligible if they had no clear indication and no clear con-
traindication for aspirin treatment, and had no clinically signifi-
cant co-existing conditions. No age limits were applied. Two pre-
defined combined primary efficacy endpoints were composed as
follows: first, non-fatal MI, non-fatal stroke, or death from cardio-
vascular causes; second, non-fatalMI, non-fatal stroke, pulmonary
embolism, major venous thrombosis, or death from cardiovascu-
lar causes. The secondary endpoints involved the following single
events: fatal or non-fatal cerebrovascular events, fatal or non-fatal
cardiac events, minor thrombotic complications (including atypi-
cal cerebral or visual symptoms of ischaemia, erythromelalgia, and
thrombophlebitis), and major and minor thrombotic complica-
tions as previously defined. The safety of low-dose aspirin was
assessed by examining rates of fatal and non-fatal major haem-
orrhage (any haemorrhage requiring transfusion, hospitalisation,
or both), minor haemorrhage, and any adverse events leading to
discontinuation of treatment. Aspirin significantly reduced only
the second of the combined endpoints. All-cause mortality and
cardiovascular mortality were not reduced significantly. The inci-
dence of major bleeding episodes was not significantly increased
in the aspirin group. The study was planned to have a follow-up
duration of five years, but as the result of a slow recruitment rate
after two years, the study was prematurely stopped. Total follow-
up consisted of 1478 person-years, with a minimum of 12 months
per participant.
Excluded studies
The reasons for exclusion are specified in the Characteristics of
excluded studies table.We excluded one study because of the short-
term duration of the study (60 days) (Finelli 1991) and another
one because it compared antiplatelet therapy with cytoreductive
therapy (Tartaglia 1986).
Risk of bias in included studies
The ECLAP 2004 and GISP 1997 studies were double-blind,
placebo-controlled, randomised trials (Characteristics of included
studies, Figure 1). We judged the methodology of the GISP study
to have a moderate quality. This judgement was based on the
fact that selective loss to follow-up or study withdrawal (8% of
participants) could not be excluded because data in the published
article were insufficient. The authors provided no further data.
The study protocol of the ECLAP study was published in advance,
before the study had been completed (Landolfi 1997). We also
considered this study to have a moderate quality, because we could
not determine whether there was selective loss to follow-up or
study withdrawal (6%). The authors provided no further data.
Allocation
Both trials had a co-ordinating centre that randomly allocated
participants.
Blinding
Randomisation was double blind, centrally co-ordinated, and
stratified by centre for both trials.
Incomplete outcome data
In both studies, loss to follow-up or study withdrawal (more than
5% in both trials) could not be excluded because data in the pub-
lished article were insufficient.
Selective reporting
It is unclear in both studies whether selective reporting occurred,
because the authors did not provide further data.
Effects of interventions
See: Summary of findings for the main comparison
Data from two trials assessing the efficacy of low-dose aspirin in
a total of 630 people with polycythaemia vera were available. The
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primary efficacy outcome in both trials was the sum of fatal arterial
and venous thrombotic events.
Published data from both studies were insufficient for a time-
to-event data analysis and for some of the planned primary and
secondary outcomes. We contacted the corresponding authors of
the GISP and ECLAP studies (the same for both studies) for ad-
ditional data, but they did not provide them. Consequently, we
meta-analysed four main outcomes as simple binary endpoints,
measuring the OR with 95% CI.
Low-dose aspirin treatment showed a marked benefit in terms
of mortality from thrombotic events, although this finding was
not statistically significant (OR 0.20, 95% CI 0.03 to 1.14, P
= 0.07, fixed-effect model; see Figure 3). In absolute terms, 3
of 1000 participants treated with aspirin had a fatal thrombotic
event, compared with 22 participants treated with placebo (risk
difference 1.9%, 95% CI 0% to 4%).
Figure 3. Forest plot of comparison: 1 Polycythaemia vera, outcome: 1.1 Mortality for thrombotic events.
A non-significant benefit of aspirin was also shown for all-cause
mortality (OR 0.46, 95% CI 0.21 to 1.01; P = 0.05; fixed-effect
model; see Figure 4).
Figure 4. Forest plot of comparison: 1 Polycythaemia vera, outcome: 1.2 All cause mortality.
The primary safety outcome in our review was mortality from
bleeding, but no data were available. A non-significant increase
with aspirin treatment was shown only for minor bleeding (OR
1.85, 95% CI 0.90 to 3.79; P = 0.09; fixed-effect model; see
Figure 5). Major bleeding occurred at a similar incidence in both
treatment groups (OR 0.99, 95%CI 0.23 to 4.36; P = 0.99; fixed-
effect model; see Figure 6).
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Figure 5. Forest plot of comparison: 1 Polycythaemia vera, outcome: 1.4 Minor bleeding.
Figure 6. Forest plot of comparison: 1 Polycythaemia vera, outcome: 1.3 Major bleeding.
Using a random-effects model for each outcome, we obtained very
similar results.
Insufficient data prevented meta-analysis of the following sec-
ondary outcomes: MI, unstable angina, ischaemic stroke, TIA,
acute peripheral and visceral thromboembolism, deep venous
thrombosis, pulmonary embolism, unusual sites of venous throm-
bosis (visceral vein thrombosis and cerebral sinus and ve-
nous thrombosis), superficial venous thrombosis, erythromelalgia,
seizures, migraine, vertigo, tinnitus, scintillating scotomas, amau-
rosis fugax, and all adverse events (Secondary outcomes).
Overall, even though no outcome was statistically significant, we
would expect 19 fatal thrombotic events (95% CI 0 to 40) to be
prevented for every 1000 participants treatedwith aspirin, without
an excess of major bleeding.
D I S C U S S I O N
Summary of main results
This systematic review of RCTs on the effects of antiplatelet drugs
for long-term primary and secondary prophylaxis of arterial and
venous thrombotic events in participants with polycythaemia vera
or essential thrombocythaemia included two original RCTs. These
were designed and performed by the same network of haematolo-
gists and included only participants with polycythaemia vera. The
experimental antiplatelet agentwas low-dose aspirin in bothRCTs.
Published data from both studies were insufficient for a time-to-
event data analysis and for some of the primary and secondary
outcomes that we had planned.
Overall, available evidence showed a marked, but not statistically
significant, beneficial effect of low-dose aspirin treatment com-
pared with placebo in terms of mortality from thrombotic events
and all-cause mortality, with no increase in major bleeding, in
participants with polycythaemia vera with no clear indication or
contraindication to aspirin.
Overall completeness and applicability of
evidence
For correct interpretation of these data, some comments are nec-
essary. We had planned to extract the HRs and associated vari-
ances for a time-to-event data meta-analysis. However, the nec-
essary data (such as several single secondary outcomes) were not
available in the published articles and could not be obtained from
the trial investigators. This means that the overall treatment effect
may be estimated with bias. For this reason, we decided to report
data as simple binary outcomes and only data from four available
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efficacy and safety outcomes (mortality from thrombotic events,
all-cause mortality, and major and minor bleeding).
We could not perform our planned subgroup analysis. Conse-
quently, results of these meta-analyses are not directly extensible
to all thrombotic risk groups of polycythaemic participants. Both
RCTs included only participants with no clear indication for as-
pirin treatment and no clear contraindication to it, and who had
no clinically significant co-existing conditions.
Moreover, no studies in participants with essential thrombo-
cythaemia have been published. Given the different natural course
of the two diseases, data pertaining to participants with poly-
cythaemia vera are only indirectly applicable to thrombocythaemic
participants. Further studies are necessary to clarify the role of an-
tiplatelet therapy in the treatment of patients with these condi-
tions. Unfortunately, no ongoing RCTs that potentially meet our
inclusion/exclusion criteria were identified for essential thrombo-
cythaemia.
Aspirin was the only antiplatelet drug that was investigated. Other
antiplatelet drugs are currently used daily (Alvarez-Larran 2010),
but no information for clinical practice can be extrapolated from
our systematic review. The only ongoing trial on this topic is a
phase II study on the safety and efficacy of clopidogrel and as-
pirin for the treatment of polycythaemia vera (ISCLAP). Lack of
research in this area may have two possible explanations: com-
plexity in conducting a trial in rare chronic diseases; and com-
peting trials on new drugs, the Janus kinase 2 inhibitors, for the
management of chronic Philadelphia-negative myeloproliferative
neoplasms (Pardanani 2011).
Quality of the evidence
Another limitation is represented by the methodological quality
of the included RCTs (Characteristics of included studies). Both
studies were well designed (ECLAP 2004, GISP 1997). However,
they were judged to have a moderate quality because insufficient
data were available to exclude an attrition bias.
Potential biases in the review process
An important limit of our meta-analysis is the relevant weight (al-
most 80%) of the ECLAP 2004 study. However, we decided to
meta-analyse data as the GISP 1997 study had a very similar pro-
tocol, and because meta-analysis is particularly useful in rare dis-
eases, such as polycythaemia vera, in which only a limited number
of participants can be enrolled.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, this systematic review is the first
ever published on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients with polycythaemia vera who have no clear indication
or contraindication to aspirin therapy, the use of low-dose aspirin,
when compared with no treatment, is associated with a statistically
non-significant reduction in the risk of fatal thrombotic events
and all-cause mortality, without increased risk of major bleeding.
Given the available evidence and until new data are published.
low-dose aspirinwould therefore be the antiplatelet drug of choice.
Implications for research
Even though polycythaemia vera and essential thrombocythaemia
are rare diseases, further RCTs are necessary to clarify definitively
which subgroup of patients may benefit from antiplatelet drugs.
Aspirin should be the drug of choice to be tested in future trials.
However, other antiplatelet drugs should also be tested to deter-
mine whether they are as beneficial and safe as aspirin, as some
patients with polycythaemia vera and essential thrombocythaemia
may have an absolute contraindication to aspirin (e.g. allergy).
A C K N OW L E D G E M E N T S
None
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ECLAP 2004
Methods Randomised controlled trial.
Participants 518 people with polycythaemia vera (210 females, 308 males; mean age 61 years: a total
of 26 percent of participants were 70 years of age or older). Participants were eligible
if they had no clear indication for aspirin treatment and no clear contraindication to
it, were able to provide written informed consent, and had no clinically significant co-
existing conditions
Interventions Low-dose aspirin, 100 mg per day (N = 253) versus placebo (N = 265). All participants
who were recruited received other recommended treatments: Phlebotomy, cytoreductive
drugs, and standard cardiovascular drugs were given as required
Outcomes The two pre-defined primary composed efficacy endpoints were: non-fatal myocardial
infarction, non-fatal stroke, or death from cardiovascular causes; and non-fatal myocar-
dial infarction, non-fatal stroke, pulmonary embolism, major venous thrombosis, or
death from cardiovascular causes
The secondary endpoints consisted of fatal or non-fatal cerebrovascular events, fatal or
non-fatal cardiac events, minor thrombotic complications (including atypical cerebral or
visual symptoms of ischaemia, erythromelalgia, and thrombophlebitis), and major and
minor thrombotic complications as previously defined
Safety was assessed by examining rates of fatal and non-fatal major haemorrhage (any
haemorrhage requiring transfusion, hospitalisation, or both), minor haemorrhage, and
any adverse events leading to discontinuation of treatment
Notes Cytoreductive therapy was used in the following percentages of participants:
- Phlebotomy: 175 participants (69.2%) in the aspirin group and 197 participants (74.
3%) in the placebo group
- Any cytoreductive drug (radioactive phosphorus, hydroxyurea, busulfan, chlorambucil,
pipobroman, interferon alpha): 149 participants (58.9%) in the aspirin group and 145
participants (54.7%) in the placebo group
After a planned interim safety analysis (in December 2000), the steering committee
was informed that fewer centres than expected were recruiting effectively; that after the
planned two years of recruitment, the rate of randomisation was reduced to nearly zero;
that an impractically long follow-up period would be required to accumulate the number
of events needed to reach the pre-defined rate of end points; and that no additional
support for the trial could be obtained. For these reasons, the study was stopped, and
follow-up of participants who had undergone randomisation was completed during the
next 12 months. These decisions were made with the advice and consent of the data
and safety monitoring board and were communicated to the investigators, who were
monitored to ensure that they conducted a final follow-up visit. We obtained updated
follow-up information after September 1, 2001, for 92% of the participants who had
undergone randomisation, for a total duration of follow-up of 1478 person-years
Risk of bias
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ECLAP 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’... A double-blind, placebo-controlled design was used.
A total of 253 participants were randomly assigned to
receive aspirin (100 mg daily), and 265 were randomly
assigned to receive placebo ... Participants were assigned
to treatments with the use of a program based on the
biased-coin algorithm, which allowed for stratification
according to centre ...’
Allocation concealment (selection bias) Low risk ’... randomisation was centralised and was performed
over the telephone ...’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inability to judge whether there was selective loss to fol-
low-up or study withdrawal (6%). No further data were
provided by the authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’... A double-blind, placebo-controlled design was used.
A total of 253 participants were randomly assigned to
receive aspirin (100 mg daily), and 265 were randomly
assigned to receive placebo ... Participants were assigned
to treatments with the use of a program based on the
biased-coin algorithm, which allowed for stratification
according to centre ...’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’... The validation of the clinical events included in the
primary endpoints was ensured by an ad hoc commit-
tee of expert clinicians who were unaware of the treat-
ment-group assignments. Each event was validated inde-
pendently by two evaluators, and disagreement between
evaluators was assessed by the chairman of the study ...’
GISP 1997
Methods Randomised controlled trial.
Participants 112 participants with polycythaemia vera (42 females, 70 males; aged 17 to 80 years), in
whom physicians were uncertain whether aspirin was indicated. Participants were ineligi-
ble if physicians were reasonably certain that aspirin was indicated, was not indicated, or
was contraindicated. Moreover, exclusion criteria included stage III chronic renal failure,
active gastrointestinal disease, and a history of a major haemorrhagic episodes during
the preceding four months
Interventions Low-dose aspirin, 40 mg per day (N = 60), versus placebo (N = 52) (in addition to the
standard management policies adopted by the participating centres)
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GISP 1997 (Continued)
Outcomes Primary endpoints: major haemorrhagic events, compliance with the assigned treatment,
gastric intolerance
Secondary endpoints: acute myocardial infarction, transient ischaemic attacks, stroke,
venous thromboembolism, and acute arterial thrombosis
Follow-up duration: 16 ± 6 months.
Notes No data on concomitant cytoreductive therapy are provided in the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’... Participants were randomly allocated ... Randomisa-
tion was double blind, centrally co-ordinated, and strat-
ified by centre and according to thrombotic risk ...’
Allocation concealment (selection bias) Low risk ’... Randomisation was double blind, centrally co-ordi-
nated, and stratified by centre and according to throm-
botic risk ...’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This judgement was based on the fact that selective loss
to follow-up or study withdrawal (8% of participants)
could not be excluded because data in the published
articlewere insufficient. The authors providedno further
data
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’... Participants were randomly allocated to receive active
treatment, ..., or placebo ... Randomisation was double
blind, centrally co-ordinated, and stratified by centre and
according to thrombotic risk ...’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’... Randomisation was double blind, centrally co-ordi-
nated, and stratified by centre and according to throm-
botic risk ... All randomised participants were seen by
their haematologists every 3 months and underwent a
clinical and laboratory evaluation of their status ... ’
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Finelli 1991 Participants with polycythaemia vera and an additional cardiovascular risk factor were randomly assigned to ticlo-
pidine (250 mg twice a day) or to placebo for 60 days. As the main objective of our systematic review is to examine
the benefit and harm of long-term antiplatelet drug administration in preventing thrombotic events compared with
no treatment, study drug administration less than 6 months is an exclusion criterion
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(Continued)
Tartaglia 1986 Participants with a diagnosis of polycythaemia vera were randomly assigned to phlebotomy plus aspirin (300 mg
three times a day) and dipyridamole (75 mg three times a day), or to phlebotomy plus radioactive phosphorus. As
the main objective of our systematic review is to examine the benefit and harm of antiplatelet drugs in preventing
thrombotic events compared with no treatment, direct comparison with an active cytoreductive drug is an exclusion
criterion
Characteristics of ongoing studies [ordered by study ID]
ISCLAP
Trial name or title Clopidogrel and Aspirin for the Treatment of Polycythemia Vera (ISCLAP)
Methods Randomised controlled trial, phase II.
Participants Inclusion criteria:
Participants are included in the study if all of the following criteria are met:
A documented diagnosis of polycythaemia vera established within 5 years of registration. There must be
documentation that the participant has met the revised WHO criteria for the diagnosis of polycythaemia
vera. Participants must meet the 2 major criteria and 1 of the minor criteria. To verify that the criteria have
been met, appropriate laboratory or pathology reports must be submitted demonstrating that the participant
has documentation of these diagnostic criteria.
Major criteria:
Hemoglobin >18.5 g/dL in men, >16.5 g/dL in women, or other evidence of increased red cell volume.
Presence of JAK 2V617F or other functionally similar mutation such as JAK2 exon 12 mutation.
Minor criteria:
Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent
erythroid, granulocyte, and megakaryocytic proliferation.
Serum erythropoietin level below the reference range for normal.
Endogenous erythroid colony formation in vitro.
High cardiovascular risk due to a prior vascular event such as ischaemic stroke, MI, or venous thromboem-
bolism. Objective documentation of these events must be accurately reviewed and registered. Stroke and
pulmonary embolism must be documented by an imaging study, deep vein thrombosis by ultrasound or
other objective methods, and MI by typical electrocardiogram (ECG) changes and/or an increase in serum
troponin. Minor thrombotic events such as TIAs, superficial thrombophlebitis, or atypical microcirculatory
disturbances alone or in combination are considered to be qualifying events
No contraindication to aspirin use such as allergy, a history of a previous hemorrhagic stroke, or a major
gastrointestinal bleed in the previous three months
Use of hydroxyurea as a cytoreductive agent.
Signed informed consent: Participants must have signed consents for both the ISCLAP protocol and for the
mandatory correlative biomarker MPD-RC 107 protocol to be eligible
Serumbilirubin levels less than and/or equal to two times the upper limit of the normal range for the laboratory
(ULN)
Serum glutamic-pyruvic transaminase (SGPT) alanine aminotransferase (ALT) levels and serum aspartate
aminotransferase (AST) less than and/or equal to 2 x ULN
Serum creatinine levels less than and/or equal to 1.5 x ULN.
Women of childbearing potential must have a negative serum or urine pregnancy test before receiving clopi-
dogrel treatment and should be advised to avoid becoming pregnant. Women of childbearing potential must
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ISCLAP (Continued)
practice effective methods of contraception (those generally accepted as standard-of-care measures). Women
of childbearing potential are those who have not been menopausal for 12 months or who have not undergone
previous surgical sterilization. If the participant is a woman of childbearing potential, shemust use a medically
acceptable form of contraception during the study period and for 30 days thereafter
Age greater than or equal to 18 years to 81 years of age.
Exclusion criteria:
Participants are excluded from this study if one or more of the following criteria are met:
Therapy with clopidogrel within the last 12 months.
Any history of prior treatment with aspirin that has resulted in a significant clinical adverse event requiring
discontinuation of aspirin therapy (e.g. bleeding, GI intolerance, etc., or intolerance to aspirin)
Participants requiring anticoagulation treatment with warfarin, heparin, or low-molecular-weight heparin for
any medical condition
Nursing and pregnant female participants. Should a woman become pregnant or suspect that she is pregnant
while participating in this study, she should inform her physician immediately
History of a major bleeding event (requiring blood transfusion or hospitalisation, bleeding at a critical site,
or life-threatening bleeding)
Clinical indication for the use of clopidogrel and/or a different antithrombotic regimen
History of active substance or alcoholic abuse within the last year
Known hypersensitivity or contraindication to study treatments
Chronic viral hepatitis or chronic liver disease from any other cause associated with a Model for End-Stage
Liver Disease (MELD) score equal to or higher than 8
Presence of any disease (e.g. cancer) that is likely to significantly shorten life expectancy
>81 years of age.
New York Heart Association (NYHA) Grade II or greater congestive heart failure
A history of gastrointestinal bleeding in the last 12 months
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days, or anticipation of the
need for a major surgical procedure during the course of the study
Biopsy or other minor surgical procedure, excluding placement of a vascular access device or bone marrow
biopsy, within 7 days before study enrolment
Ongoing serious, non-healing wound, ulcer, or bone fracture.
Treatment with a CYP3A4 inhibitor, including azole antifungals (topicals are permitted); protease inhibitors;
nefazodone; cyclosporine; erythromycin; clarithromycin; and troleandomycin
Serum AST greater than or equal to 2 x ULN.
Serum ALT greater than or equal 2 x ULN.
Total bilirubin greater than or equal to 2 x ULN,
Serum creatinine greater than or equal 1.5 x ULN.
Participants with a diagnosis of polycythaemia vera >5 years from the time of registration
Participants who do not have high-risk polycythaemia vera as defined by experiencing a thrombotic event
occurring since the initial diagnosis of PV
Interventions Clopidogrel (oral, 75 mg per day) versus placebo, in addition to low-dose aspirin and hydroxyurea
Outcomes Primary outcome measures: to determine the safety of clopidogrel plus aspirin in participants with poly-
cythaemia at 2 years of follow-up
Starting date June 2009.
Contact information Raffaele Landolfi (rlandolfi@rm.unicatt.it) on behalf of Myeloproliferative Disorders-Research Consortium
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ISCLAP (Continued)
Notes http://clinicaltrials.gov, last updated on June 24, 2011: ’the study has been terminated (could not get drug).’
No data have been published yet.
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D A T A A N D A N A L Y S E S
Comparison 1. Polycythaemia vera
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality for thrombotic events 2 630 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.03, 1.14]
2 All cause mortality 2 630 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.21, 1.01]
3 Major bleeding 2 630 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.23, 4.36]
4 Minor bleeding 2 630 Odds Ratio (M-H, Fixed, 95% CI) 1.85 [0.90, 3.79]
WH A T ’ S N E W
Last assessed as up-to-date: 31 October 2012.
Date Event Description
31 October 2012 New citation required but conclusions have not
changed
Search has been re-run to 12 October 2012. Only an
ongoing study was included in this update
12 October 2012 New search has been performed New search
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 2, 2008
Date Event Description
13 January 2011 Amended typo correction
15 August 2008 Amended Converted to new review format.
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